Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Current Assets (2019 - 2025)

Benitec Biopharma has reported Current Assets over the past 7 years, most recently at $189.6 million for Q4 2025.

  • Quarterly results put Current Assets at $189.6 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $189.6 million (changed N/A YoY), and the annual figure for FY2025 was $98.5 million, up 90.65%.
  • Current Assets reached $189.6 million in Q4 2025 per BNTC's latest filing, up from $95.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $189.6 million in Q4 2025 and bottomed at $3.7 million in Q2 2023.
  • Median Current Assets over the past 5 years was $17.1 million (2022), compared with a mean of $41.2 million.
  • The largest annual shift saw Current Assets crashed 76.61% in 2022 before it soared 1285.73% in 2024.
  • Over 5 years, Current Assets stood at $12.7 million in 2021, then dropped by 13.39% to $11.0 million in 2022, then surged by 89.49% to $20.8 million in 2023, then surged by 228.6% to $68.3 million in 2024, then skyrocketed by 177.45% to $189.6 million in 2025.
  • Business Quant data shows Current Assets for BNTC at $189.6 million in Q4 2025, $95.1 million in Q3 2025, and $98.5 million in Q2 2025.